vs

Side-by-side financial comparison of Cannae Holdings, Inc. (CNNE) and NEOGENOMICS INC (NEO). Click either name above to swap in a different company.

NEOGENOMICS INC is the larger business by last-quarter revenue ($186.7M vs $103.3M, roughly 1.8× Cannae Holdings, Inc.). NEOGENOMICS INC runs the higher net margin — -57.9% vs -90.0%, a 32.2% gap on every dollar of revenue. On growth, NEOGENOMICS INC posted the faster year-over-year revenue change (11.1% vs -6.0%). Over the past eight quarters, NEOGENOMICS INC's revenue compounded faster (6.5% CAGR vs -3.4%).

Cannae Holdings, Inc. is a diversified holding company that primarily invests in and operates businesses across multiple sectors including financial services, restaurant and hospitality, technology, and healthcare. Its core market is the United States, and it focuses on driving long-term stakeholder value through active portfolio management and strategic operational support for its portfolio companies.

NeoGenomics Laboratories, Inc., also known as NeoGenomics or Neo, is an American CLIA-certified clinical laboratory, pharma services and information services company that specializes in cancer genetics diagnostic testing. The company's testing services include cytogenetics, fluorescence in situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology, and molecular genetics.

CNNE vs NEO — Head-to-Head

Bigger by revenue
NEO
NEO
1.8× larger
NEO
$186.7M
$103.3M
CNNE
Growing faster (revenue YoY)
NEO
NEO
+17.1% gap
NEO
11.1%
-6.0%
CNNE
Higher net margin
NEO
NEO
32.2% more per $
NEO
-57.9%
-90.0%
CNNE
Faster 2-yr revenue CAGR
NEO
NEO
Annualised
NEO
6.5%
-3.4%
CNNE

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
CNNE
CNNE
NEO
NEO
Revenue
$103.3M
$186.7M
Net Profit
$-93.0M
$-108.0M
Gross Margin
15.2%
43.3%
Operating Margin
-23.3%
Net Margin
-90.0%
-57.9%
Revenue YoY
-6.0%
11.1%
Net Profit YoY
-101.7%
42.0%
EPS (diluted)
$-2.09
$-0.13

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CNNE
CNNE
NEO
NEO
Q1 26
$186.7M
Q4 25
$103.3M
$190.2M
Q3 25
$106.9M
$187.8M
Q2 25
$110.2M
$181.3M
Q1 25
$103.2M
$168.0M
Q4 24
$109.9M
$172.0M
Q3 24
$113.9M
$167.8M
Q2 24
$118.0M
$164.5M
Net Profit
CNNE
CNNE
NEO
NEO
Q1 26
$-108.0M
Q4 25
$-93.0M
Q3 25
$-68.4M
$-27.1M
Q2 25
$-238.8M
$-45.1M
Q1 25
$-113.0M
$-25.9M
Q4 24
$-46.1M
Q3 24
$-13.6M
$-17.7M
Q2 24
$-155.0M
$-18.6M
Gross Margin
CNNE
CNNE
NEO
NEO
Q1 26
43.3%
Q4 25
15.2%
43.8%
Q3 25
17.1%
42.8%
Q2 25
17.6%
42.6%
Q1 25
11.8%
43.6%
Q4 24
16.4%
44.9%
Q3 24
18.3%
44.6%
Q2 24
21.9%
44.1%
Operating Margin
CNNE
CNNE
NEO
NEO
Q1 26
Q4 25
-23.3%
-7.1%
Q3 25
-12.3%
-14.4%
Q2 25
-55.3%
-26.3%
Q1 25
-20.7%
-16.6%
Q4 24
-20.0%
-10.7%
Q3 24
-15.9%
-12.6%
Q2 24
-19.5%
-13.3%
Net Margin
CNNE
CNNE
NEO
NEO
Q1 26
-57.9%
Q4 25
-90.0%
Q3 25
-64.0%
-14.4%
Q2 25
-216.7%
-24.9%
Q1 25
-109.5%
-15.4%
Q4 24
-41.9%
Q3 24
-11.9%
-10.5%
Q2 24
-131.4%
-11.3%
EPS (diluted)
CNNE
CNNE
NEO
NEO
Q1 26
$-0.13
Q4 25
$-2.09
Q3 25
$-1.25
Q2 25
$-3.93
Q1 25
$-1.81
Q4 24
$-0.75
Q3 24
$-0.22
Q2 24
$-2.49

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CNNE
CNNE
NEO
NEO
Cash + ST InvestmentsLiquidity on hand
$182.0M
$146.1M
Total DebtLower is stronger
$70.8M
Stockholders' EquityBook value
$1.0B
$828.8M
Total Assets
$1.3B
$1.3B
Debt / EquityLower = less leverage
0.07×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CNNE
CNNE
NEO
NEO
Q1 26
$146.1M
Q4 25
$182.0M
$159.6M
Q3 25
$233.8M
$164.1M
Q2 25
$66.7M
$154.7M
Q1 25
$126.2M
$346.2M
Q4 24
$131.5M
$367.0M
Q3 24
$362.0M
Q2 24
$355.1M
Total Debt
CNNE
CNNE
NEO
NEO
Q1 26
Q4 25
$70.8M
$341.9M
Q3 25
$68.6M
Q2 25
$168.4M
Q1 25
$170.6M
Q4 24
$181.0M
$541.1M
Q3 24
$181.2M
Q2 24
$78.2M
Stockholders' Equity
CNNE
CNNE
NEO
NEO
Q1 26
$828.8M
Q4 25
$1.0B
$836.6M
Q3 25
$1.2B
$838.3M
Q2 25
$1.4B
$854.0M
Q1 25
$1.7B
$888.3M
Q4 24
$1.8B
$902.3M
Q3 24
$1.9B
$908.2M
Q2 24
$1.9B
$915.9M
Total Assets
CNNE
CNNE
NEO
NEO
Q1 26
$1.3B
Q4 25
$1.3B
$1.4B
Q3 25
$1.5B
$1.4B
Q2 25
$1.8B
$1.4B
Q1 25
$2.1B
$1.6B
Q4 24
$2.2B
$1.6B
Q3 24
$2.3B
$1.6B
Q2 24
$2.2B
$1.6B
Debt / Equity
CNNE
CNNE
NEO
NEO
Q1 26
Q4 25
0.07×
0.41×
Q3 25
0.06×
Q2 25
0.12×
Q1 25
0.10×
Q4 24
0.10×
0.60×
Q3 24
0.10×
Q2 24
0.04×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CNNE
CNNE
NEO
NEO
Operating Cash FlowLast quarter
$16.0M
$-8.1M
Free Cash FlowOCF − Capex
$12.0M
FCF MarginFCF / Revenue
11.6%
Capex IntensityCapex / Revenue
3.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-28.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CNNE
CNNE
NEO
NEO
Q1 26
$-8.1M
Q4 25
$16.0M
$1.3M
Q3 25
$-21.6M
$8.9M
Q2 25
$-21.6M
$20.3M
Q1 25
$9.1M
$-25.3M
Q4 24
$-12.0M
$9.8M
Q3 24
$-31.9M
$9.2M
Q2 24
$-10.2M
$13.9M
Free Cash Flow
CNNE
CNNE
NEO
NEO
Q1 26
Q4 25
$12.0M
$-6.5M
Q3 25
$-24.1M
$570.0K
Q2 25
$-23.6M
$14.0M
Q1 25
$7.2M
$-29.8M
Q4 24
$-14.4M
$-1.8M
Q3 24
$-33.6M
$-1.6M
Q2 24
$-11.8M
$814.0K
FCF Margin
CNNE
CNNE
NEO
NEO
Q1 26
Q4 25
11.6%
-3.4%
Q3 25
-22.5%
0.3%
Q2 25
-21.4%
7.7%
Q1 25
7.0%
-17.8%
Q4 24
-13.1%
-1.0%
Q3 24
-29.5%
-0.9%
Q2 24
-10.0%
0.5%
Capex Intensity
CNNE
CNNE
NEO
NEO
Q1 26
Q4 25
3.9%
4.1%
Q3 25
2.3%
4.4%
Q2 25
1.8%
3.5%
Q1 25
1.8%
2.7%
Q4 24
2.2%
6.7%
Q3 24
1.5%
6.4%
Q2 24
1.4%
8.0%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CNNE
CNNE

Reportable Segment Aggregation Before Other Operating Segment$94.9M92%
Other Operating Revenue$8.4M8%

NEO
NEO

Segment breakdown not available.

Related Comparisons